Drugs in Dev.
Obstetrics/Gynecology (Women’s Health)
Phase III
China 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Relugolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Relugolix is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Menorrhagia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 04, 2024
Lead Product(s) : Relugolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Asieris Announces NDA Acceptance for Regulatory Review of Cevira in China
Details : APL-1702 (cevira) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions, licensed to Asieris by Photocure.
Product Name : Cevira
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2024
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GenSci094
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Sixth Affiliated Hospital, Sun Yat-sen University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GenSci094 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 19, 2023
Lead Product(s) : GenSci094
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Sixth Affiliated Hospital, Sun Yat-sen University
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SHR7280
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SHR7280 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility, Female.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : SHR7280
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Elagolix Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elagolix is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Endometriosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 13, 2022
Lead Product(s) : Elagolix Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QL1012
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of QL1012 in Women for Assisted Reproductive Treatment
Details : QL1012 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 08, 2021
Lead Product(s) : QL1012
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Asieris has received Clinical Trial Approval from China NMPA for the global, multi-centered Phase III clinical trial of its photodynamic drug-device combination product Cevira®, which is being developed for the non-surgical treatment of high-grade cerv...
Product Name : Cevira
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2020
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Peking University Third Hospital | The First Affiliated Hospital with Nanjing Medical University | Women’s Hospital, Zhejiang University School of Medicine | Xiangya Hospital, Central South University | Sixth Affiliated Hospital, Sun Yat-sen University |
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET
Details : Triptorelin is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ovarian Hyperstimulation Syndrome.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 06, 2017
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Peking University Third Hospital | The First Affiliated Hospital with Nanjing Medical University | Women’s Hospital, Zhejiang University School of Medicine | Xiangya Hospital, Central South University | Sixth Affiliated Hospital, Sun Yat-sen University |
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Follitropin Alfa
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Peking University People's Hospital | Peking University First Hospital | Reproductive & Genetic Hospital of CITIC-Xiangya | Qilu Hospital of Shandong University | Wuhan Union Hospital | Second Hospital of Jilin University | Shengjing Hospital | The First
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gonal-f (Follitropin Alfa) is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anovulation.
Product Name : Gonal-f
Product Type : Hormone
Upfront Cash : Inapplicable
January 12, 2015
Lead Product(s) : Follitropin Alfa
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Peking University People's Hospital | Peking University First Hospital | Reproductive & Genetic Hospital of CITIC-Xiangya | Qilu Hospital of Shandong University | Wuhan Union Hospital | Second Hospital of Jilin University | Shengjing Hospital | The First
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
Details : Levonorgestrel is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Contraceptives, Oral.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
December 27, 2013
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
